mosapride has been researched along with Idiopathic Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asahina, M; Hattori, T; Ito, T; Liu, Z; Odaka, T; Sakakibara, R; Uchiyama, T; Yamaguchi, K; Yamaguchi, T; Yamamoto, T | 1 |
| Asai, H; Hirano, M; Kameyama, M; Kubori, T; Minami, T; Nishinaka, K; Oda, M; Udaka, F; Ueno, S | 1 |
2 trial(s) available for mosapride and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
Topics: Aged; Benzamides; Colon; Constipation; Female; Functional Laterality; Gastrointestinal Transit; Humans; Male; Middle Aged; Morpholines; Parkinson Disease; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT4 Receptor Agonists; Treatment Outcome; Video Recording | 2005 |
Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzamides; Female; Gastric Emptying; Gastrointestinal Motility; Humans; Levodopa; Morpholines; Parkinson Disease; Positron-Emission Tomography; Receptors, Serotonin, 5-HT4; Serotonin Receptor Agonists; Stomach | 2005 |